The purpose of this study was to analyze the usage of amphotericin B desoxycholate in a small community hospital, with special emphasis on its side effects and need for premedication. We performed a retrospective chart review for patients who received intravenous amphotericin B from January 1993 to May 1996. Temperature elevation, clinical symptoms during infusion, need for premedication, and fluctuations in serum potassium and creatinine values were especially noted. Statistical analysis showed that toxicity indicated by laboratory values (laboratory toxicity) increased with increasing amphotericin B dose, but clinical side-effects decreased with advancing age. Clinical side effects were not associated with total amphotericin B dosage; laboratory toxicity in our study was not more prevalent in elderly patients. The main finding of this study was that most patients tolerate amphotericin B well and only 23% of patients needed premedication. Our fungal cure rate was 83%. New, expensive preparations of amphotericin B should be reserved for the small subset of patients who either are intolerant of amphotericin B desoxycholate or need high doses for systemic fungal infections.
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The purpose of this study was to analyze the usage of amphotericin B desoxycholate in a small community hospital, with special emphasis on its side effects and need for premedication. We performed a retrospective chart review for patients who received intravenous amphotericin B from January 1993 to May 1996. Temperature elevation, clinical symptoms during infusion, need for premedication, and fluctuations in serum potassium and creatinine values were especially noted. Statistical analysis showed that toxicity indicated by laboratory values (laboratory toxicity) increased with increasing amphotericin B dose, but clinical side-effects decreased with advancing age. Clinical side effects were not associated with total amphotericin B dosage; laboratory toxicity in our study was not more prevalent in elderly patients. The main finding of this study was that most patients tolerate amphotericin B well and only 23% of patients needed premedication. Our fungal cure rate was 83%. New, expensive preparations of amphotericin B should be reserved for the small subset of patients who either are intolerant of amphotericin B desoxycholate or need high doses for systemic fungal infections.
With the use of broad-spectrum antibiotics, immunosuppresamphotericin B as well as the need for premedication, we conducted a retrospective study of amphotericin B use in a sion, and long-term intravenous catheters, the incidence of fungemia has risen fivefold to 10-fold in the past 2 decades small urban community hospital over a 40-month period. [1 -3] . In spite of the advent of imidazole agents, amphotericin B is still considered the ''gold standard'' of antifungal therapy Methods [4] . Previous investigators have reported a high incidence of amphotericin B side effects, often in ú50% of patients (table  Straub Hospital is a 152-bed facility in Honolulu where 1) [3, 5 -12] . Side effects most frequently include chills, fever, cardiovascular and neurological surgery is performed but not and nausea or vomiting, often with renal insufficiency and organ transplantation. We reviewed hospital records of patients hypokalemia due to amphotericin B renal tubular damage. In receiving intravenous amphotericin B from January 1993 until a recent survey of 69 hospitals, 70% of patients were given May 1996. Fungal diagnosis, underlying diseases, clinical outpremedications to prevent amphotericin B side effects [5] .
come, and reasons for discontinuing treatment were noted. In addition, both daily and total amphotericin B dosages were recorded. Age, race, and sex were studied as treatment variSee editorial response by Patterson on pages 339 -40.
ables; one of the authors (F.P.) examined 95% of these study patients. We noted temperature elevation and symptoms during Because of the toxicity associated with the desoxycholate infusion and use of premedication. Laboratory data were examcolloidal form of amphotericin B, several new formulations of ined for evidence of hypokalemia and renal insufficiency. Hyamphotericin B complexed with liposomes have been develpokalemia was defined as a serum potassium level of õ3.5 oped, resulting in greater tissue penetration and reduced nephmg/dL, and renal insufficiency was considered to be a serum rotoxicity and hypokalemia [13 -15] . These expensive new creatinine level of §1.6 mg/dL with an increase of §0.5 lipid preparations have decreased toxicity, bringing the incimg/dL during amphotericin B therapy. dence of chills and fever to as low as 1% -16% and that of Outcome for patients with proven fungal infections was evalnausea and vomiting to only 3% -9%, with virtually no nephrouated as follows. Cure was defined as eradication of fungus toxicity [13, 14] . To evaluate adverse effects of conventional from repeated cultures and resolution of symptoms due to infection. Some patients were considered unevaluable because of a change in antifungal therapy (to azoles) or an insufficient duration of therapy (õ5 days). We noted deaths due to fungal tion but had no history of amphotericin B side effects. EightyAs shown in table 2, the majority of patients received amphoone patients did not need any premedication. Twenty-two pertericin B for culturally proven fungal infections, rather than as sons (20%) received diphenylhydramine, 16 (14%) received empirical therapy. Most patients had a yeast isolated, either a acetaminophen, 13 (12%) received meperidine hydrochloride, Candida or Cryptococcus species or, in a few cases, an Asper-4 (4%) received hydrocortisone, and none received heparin. In gillus species. Fungemia, funguria, and yeast respiratory infec-81% of these cases, multiple premedications were used. As tions were the three most common clinical conditions. Eightywould be expected, 54% of premedicated patients were having three percent of patients made a full recovery from documented clinical side effects, while only 16% of those not premedicated fungal infections; 16 patients (14.4%) died while receiving amphotericin B treatment; most deaths were due to underlying illnesses. One death was directly attributable to yeast septice- cryptococcal infections the average total dose was much higher Hypokalemia 19 (294 mg).
Renal toxicity 15 We examined several variables in relation to amphotericin B toxicity. There were no significant sex or race differences in the incidence of clinical or laboratory side effects. In addition, there were no differences in racial compositions among the various age groups. Clinical side effects did not vary significantly with either daily or total amphotericin B doses. Underlying illnesses also did not affect rates of clinical or laboratory toxicities. Of 102 patients in our study, 4 had end-stage renal insufficiency.
Age was significantly associated with clinical side effects: 48% of patients between ages 22 and 49 years had chills, rigors, and/or nausea, vs. only 19.3% in older age groups (figure 1).
other reports [16, 17] . Almost all of our patients were infected There were significant differences in clinical side effects bewith a Candida or Cryptococcus species; only four were intween age groups under and over 50 years by Pearson's x 2 test fected with an Aspergillus species. Some studies have sug-(P õ .0048). Younger patients were more likely to develop gested that a cumulative dosage of 200 -400 mg is often sufficlinical side effects but comprised only 20% of our total treatcient to treat yeast infections; our average total dose of 148 ment group. There were no significant age differences in the mg for candidal infections was slightly lower. incidence of either hypokalemia or nephrotoxicity. As shown
The major emphasis of our investigation was to study side in figure 2, both hypokalemia and renal insufficiency were effects of amphotericin B, which occurred mainly in the highly correlated with total amphotericin B dosage and number younger patients. Most patients did not need premedications, of infusion days. We were unable to assess the effect of infusion in contrast with the experience of previous authors [11, 18] . time in our retrospective study since most patients were infused
In our study, 23% of the patients were premedicated (10% over 4 -5 hours (94% of all cases).
routinely and 13% after previous side effects). In contrast, Grasela et al. reported that in 69 participating hospitals, 70% Discussion of patients were medicated prior to amphotericin B infusion [11] . Nicholl et al. premedicated 80% of their patients at VanMost hospitals in the United States are community based and couver General Hospital; 85% also received 1-mg initial test have fewer than 200 beds. At our small community hospital, doses, with no anaphylactic reactions [18] . intravenous amphotericin B was used fairly frequently; primary
We agree with previous reports that found limited useuse was for yeast fungemia or funguria, and only 20% of fulness in the initial test dose of amphotericin B [4, 11] . At patients received amphotericin B empirically because they were our institution, we used a test dose only six times (5.4%), immunocompromised. Overall, we had a 83% cure rate for and like other investigators, we found that test doses are of documented infections, which compares favorably with that in little benefit [4, 11] . The incidence of clinical side effects (fever, rigor, and/or nausea) has been reported to be between 14% and 100% in previous studies (table 1) . Early studies of amphotericin B comprised mainly patients with endemic dimorphic fungal infections, such as coccidioidomycosis and blastomycosis, requiring prolonged intensive therapy associated with a higher incidence of side effects [5 -8] . Later published studies were usually of patients with candidemia, candiduria, or other systemic yeast infections, often treated with short-course therapy [3, 10, 19, 20] . Low-dose amphotericin B use at our institution was associated with a 25% incidence of clinical side effects (table 3) , similar to that in other low-dosage studies [3, 9, 11] . Several authors report that large cumulative doses cause increased clinical side effects [6, 8, 21, 22] , which may explain / 9c46$$fe50 01-08-98 22:31:40 cidas UC: CID the higher incidence of amphotericin B side effects reported as the total dose of amphotericin B increases, all patients must be monitored closely for both nephrotoxicity and hypokalemia. in older literature [6 -8] .
The incidences of nephrotoxicity and hypokalemia in our In conclusion, for the majority of our patients, amphotericin B can be given cautiously without premedication and at full study were 15% and 19%, respectively. Consistent with previous reports [8, 21, 22] , both nephrotoxicity and hypokalemia doses, but the blood pressure must be monitored frequently for the rare occurrence of anaphylaxis. Only when side effects occurred more often with higher amphotericin B doses (figure 2). As opposed to the clinical toxicity profile, there was no occur should such drugs as meperidine, hydrocortisone, or diphenylhydramine be used or the dosage of amphotericin B relationship between age and amphotericin B -induced hypokalemia or renal insufficiency. This is in contrast to the finding adjusted. Finally, expensive liposomal amphotericin B preparations are best reserved for select groups of patients intolerant in a previous study that older patients were more prone to renal damage from amphotericin B [8] . We analyzed our clinical of amphotericin B desoxycholate. and laboratory side-effect data by racial groups and found no statistically significant differences among these groups. We were unable to find previously published studies that addressed
